Elise E DeVito1, Andrea H Weinberger2,3, Raina D Pang4, Nicole Petersen5,6, Tessa Fagle1, Alicia M Allen6. 1. Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA. 2. Ferkauf Graduate School of Psychology, Yeshiva University, Bronx, New York USA. 3. Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York USA. 4. Department of Preventive Medicine, Keck School of Medicine of USC, Los Angeles, CA, USA. 5. Jane and Terry Semel Institute for Neuroscience and Human Behavior at UCLA. 6. Department of Family and Community Medicine, College of Medicine -Tucson, University of Arizona, Tucson, AZ, USA; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, Los Angeles, CA, USA.
Abstract
PURPOSE OF REVIEW: The goal was to review recent (1/2015-2/2020) evidence of impulsivity as a feature of substance use disorders or use of substances (alcohol, cannabis, nicotine, opioids, stimulants) in males compared to females in terms of: a) impulsivity in substance-using groups (or substance-using compared to control groups), and b) relationship between impulsivity and substance use behavior, clinical severity, or treatment outcomes. RECENT FINDINGS: Of 361 papers identified by the searches, 69 met inclusion criteria, and 39 were highlighted for considering sex/gender in relation to impulsivity in substance-using populations. Taken together, findings supported higher impulsivity in males and females who use substances, relative to controls; and higher impulsivity was linked with more substance use/severity in both sex/genders. There were mixed findings regarding male versus female differences in impulsivity among individuals who use substances, or in the magnitude of the relationship between impulsivity and substance use severity. SUMMARY: The current body of evidence does not point to a consistent sex/gender difference in the role of impulsivity within and across substance use disorders. Impulsivity is a clinically-relevant construct for male and female individuals who use substances, across a range of substances.
PURPOSE OF REVIEW: The goal was to review recent (1/2015-2/2020) evidence of impulsivity as a feature of substance use disorders or use of substances (alcohol, cannabis, nicotine, opioids, stimulants) in males compared to females in terms of: a) impulsivity in substance-using groups (or substance-using compared to control groups), and b) relationship between impulsivity and substance use behavior, clinical severity, or treatment outcomes. RECENT FINDINGS: Of 361 papers identified by the searches, 69 met inclusion criteria, and 39 were highlighted for considering sex/gender in relation to impulsivity in substance-using populations. Taken together, findings supported higher impulsivity in males and females who use substances, relative to controls; and higher impulsivity was linked with more substance use/severity in both sex/genders. There were mixed findings regarding male versus female differences in impulsivity among individuals who use substances, or in the magnitude of the relationship between impulsivity and substance use severity. SUMMARY: The current body of evidence does not point to a consistent sex/gender difference in the role of impulsivity within and across substance use disorders. Impulsivity is a clinically-relevant construct for male and female individuals who use substances, across a range of substances.
Entities:
Keywords:
Sex and gender and sex/gender; alcohol; cannabis; impulsivity; nicotine; opioids; poly-drug use; stimulants
Authors: Joshua L Gowin; Matthew E Sloan; Bethany L Stangl; Vatsalya Vatsalya; Vijay A Ramchandani Journal: Am J Psychiatry Date: 2017-08-04 Impact factor: 18.112
Authors: Ashwini K Pandey; Chella Kamarajan; Niklas Manz; David B Chorlian; Arthur Stimus; Bernice Porjesz Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2015-10-09 Impact factor: 5.067
Authors: Edith López-Toro; Casper J H Wolf; Rafael A González; Wim van den Brink; Arnt Schellekens; María C Vélez-Pastrana Journal: J Clin Med Date: 2022-05-19 Impact factor: 4.964
Authors: Mehdi Akbari; Mohammad Hossein Bahadori; Shahram Mohammadkhani; Daniel C Kolubinski; Ana V Nikčević; Marcantonio M Spada Journal: Addict Behav Rep Date: 2021-05-27